{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-273532","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.692589+00:00","generated_at":"2026-06-08T09:31:55.046363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Atea Pharma Q3 net loss widens to $33.1M; cash at $595.1M; pipeline milestones on track","bullets":["Net loss of $33.1M ($0.40/share) vs $8.1M ($0.10) a year ago, driven by R&D spending surge to $28.2M.","Cash, cash equivalents and marketable securities $595.1M at Sept 30, down $13M from June 30.","Phase 3 SUNRISE-3 for bemnifosbuvir in COVID-19 enrollment ongoing; first interim analysis expected Q1 2024.","Phase 2 HCV combination trial (bemnifosbuvir + ruzasvir) lead-in cohort fully enrolled; initial data also due Q1 2024.","Interest income rose to $7.9M from $4.4M on higher yields; total operating expenses $40.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-273532","json":"https://secwatch.observer/filing/0001193125-23-273532.json","markdown":"https://secwatch.observer/filing/0001193125-23-273532.md","text":"https://secwatch.observer/filing/0001193125-23-273532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523273532/0001193125-23-273532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523273532/d524760d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:31:55.046363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17456caecae334a56634544458723056476bf612","claim":"Atea Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523273532/0001193125-23-273532-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}